Supriya Lifescience shares jumped over 16% to ₹940.50 during Friday's trading session after the company reported impressive Q4FY26 results. According to reports from The Economic Times, the rally was supported by robust revenue growth, improving operational performance, and sustained demand from export markets. The pharmaceutical company demonstrated strong financial performance across all key metrics, with the stock remaining in an uptrend despite overbought technical indicators.
The company posted an impressive 47% year-on-year rise in Profit After Tax (PAT) for Q4FY26 at ₹74.23 crore, compared to ₹50.37 crore in the corresponding quarter of the previous year. As reported by The Economic Times, revenue from operations jumped 50.2% YoY to ₹276.53 crore against ₹184.11 crore in Q4FY25, reflecting strong traction across key therapeutic segments and regulated markets. EBITDA for the quarter stood at ₹97.62 crore, rising from ₹67.58 crore in the year-ago period.
For the full financial year FY26, Supriya Lifescience reported healthy growth across all major financial parameters. According to The Economic Times, revenue from operations increased 18.9% YoY to ₹827.87 crore from ₹696.48 crore in FY5. EBITDA rose 12.8% to ₹294.05 crore compared to ₹260.79 crore last year, while PAT climbed 11.3% YoY to ₹209.12 crore against ₹187.96 crore in FY5.
The anaesthetic segment continued to remain the company's key growth driver during FY26, while newly launched products in the cardiovascular and ADHD segments also witnessed encouraging traction. As reported by The Economic Times, capacity utilisation improved to 74% from 70% in FY5, aided by the ramp-up of Module E at the Lote facility and operational efficiencies. The company expanded its long-term manufacturing roadmap through strategic land acquisitions near existing facilities and at Isambe, Patalganga, while its Ambernath formulation facility commissioned five finished dosage manufacturing lines.
From a technical perspective, the stock continues to remain in a strong bullish trend, trading above all 8 out of 8 key simple moving averages (SMAs). However, according to The Economic Times, the 14-day Relative Strength Index (RSI) stands at 75.9, indicating overbought conditions. An RSI above 70 generally suggests the possibility of near-term profit booking or a temporary pullback, though the stock maintains its uptrend momentum.
